The company said, "The company currently expects full-year 2023 worldwide revenue of approximately $445 million to $455 million, an increase of 10% to 12% over prior year. This full-year 2023 guidance includes approximately $75 million to $85 million of PDN revenue, an increase of 56% to 77% over prior year. This guidance assumes the full year of 2023 will see a steady recovery and includes no significant business impact from new COVID variants or waves and its related impacts on patient willingness to seek elective care, and near-term improvement in healthcare facility restrictions and steady improvement in healthcare facility staffing limitations."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NVRO:
- Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2022 Revenue and Provides Full-Year 2023 Revenue Guidance
- Nevro downgraded to Underweight from Neutral at Piper Sandler
- Nevro upgraded to Buy from Hold at Canaccord
- Nevro announces presentation of two abstracts for PDN and NSBP
- Wells Fargo downgrades Nevro to Equal Weight, lowers price target to $43